Abstract
Simple SummarySurveillance methods for oral squamous cell carcinoma (OSCC) patients may be chosen by considering the risk of recurrence. We performed a retrospective cohort study in 324 OSCC patients after complete surgical resection as the primary treatment from 2007 to 2020 at our hospital. Regarding the time to occurrence of postsurgical events, we found that half of cases of local recurrence, cervical lymph node, and distant metastasis occurred within 200 days, and 75% of all these events occurred within 400 days. However, the mean time for second primary cancer was 1589 days. The postsurgical events were detected by imaging examinations earlier than they were by visual examination and palpation. It is desirable to perform FDG-PET/CT within 3–6 months and at 1 year after surgery and to consider CECT as an option in between FDG-PET/CT, while continuing history and physical examinations for about 5 years based on an individual risk assessment.Background: The surveillance methods oral squamous cell carcinoma (OSCC) patients may be chosen by considering the risk for recurrence, and it is important to establish appropriate methods during the period in which latent/dormant cancer cells become more apparent. To investigate the appropriate surveillance of patients with OSCC based on the individual risk for recurrence and/or metastasis, we performed a retrospective cohort study after the complete surgical resection of OSCC as the primary treatment. Methods: The study was performed in 324 patients with OSCC who had been primarily treated with surgery from 2007 to 2020 at our hospital. We investigated the period, timing, and methods (visual examination, palpation and imaging using FDG-PET/CT or CECT) for surveillance in each case that comprised postsurgical treatment. Results: Regarding the time to occurrence of postsurgical events, we found that half of cases of local recurrence, cervical lymph node metastasis, and distant metastasis occurred within 200 days, and 75% of all of these events occurred within 400 days. However, the mean time for second primary cancer was 1589 days. The postsurgical events were detected earlier by imaging examinations than they were by visual examination and palpation. Conclusions: For the surveillance of patients with OSCC after primary surgery, it is desirable to perform FDG-PET/CT within 3–6 months and at 1 year after surgery and to consider CECT as an option in between FDG-PET/CT, while continuing history and physical examinations for about 5 years based on individual risk assessment.
Highlights
Oral squamous cell carcinoma (OSCC) is mainly treated with surgery in combination with radiotherapy, chemotherapy, and immune checkpoint inhibitors
A comparison of our established risk factors showed that the outcome was significantly poorer andpreviously that the established risk factors showed that the outcome was significantly poorer and the ococcurrence of postsurgical events was higher in patients with these risk factors
The outcome was poorer in patients with risk factors compared to those without these. Based on these clinical manifestations, we considered the meaning of surveillance for factors who did not receive postsurgical treatment
Summary
Oral squamous cell carcinoma (OSCC) is mainly treated with surgery in combination with radiotherapy, chemotherapy (including molecular-targeted drugs), and immune checkpoint inhibitors. These treatments have improved the prognosis of patients with OSCC over the years, local recurrence, cervical lymph node metastasis, and distant metastasis may be observed after initial complete resection. IV or V among the AFs and defined them with the addition of the Yamamoto–Kohama (YK) mode of invasion [2,3], with YK-4C and YK-4D as the major risk factors for recurrence or metastasis [4] We have used these risk factors since 2014, and we have found that patients with these factors have significantly poorer outcomes and that these outcomes are significantly improved using combination therapy with cetuximab and paclitaxel [4,5]. The mean time for second primary cancer was 1589 days
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
